Vanderbilt Ingram Cancer Center Archives
Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors
Aug. 8, 2023—A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.
International workgroup of geneticists issues CHEK2 guidelines
Jul. 26, 2023—International workgroup issues additional guidance on how to manage patients who carry inherited CHEK2 gene mutations that put them at a higher risk for cancer.
Stem cell recipient meets donor who saved her life 10 years ago
Jul. 20, 2023—Each passing day is precious for Deneen Eastridge, but a decade is a priceless gift. The Dallas resident came to Nashville recently to meet Trina Hughes, the stem cell donor who gave her the gift of life 10 years ago.
Holowatyj receives National Cancer Institute MERIT Award
Jul. 19, 2023—Vanderbilt's Andreana Holowatyj, PhD, MSCI, has received the National Cancer Institute’s Method to Extend Research in Time Award to support her ongoing investigation into how early-onset colorectal cancer and its treatments impact reproductive health.
Study identifies key regulator of melanoma development
Jun. 29, 2023—Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.
New treatment option for metastatic colorectal cancer prolongs survival
Jun. 15, 2023—Research conducted at Vanderbilt points to a new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.
Early-onset CRC germline genetic differences identified by race, ethnicity
Jun. 15, 2023—A Vanderbilt study that delved into genetic predisposition for early-onset colorectal cancer by race and ethnicity has identified differing germline risk variants.
Study discovers that tumor mutation burden predicts survival outcome
Jun. 5, 2023—The expected course of a patient's cancer prognosis has traditionally been judged by its type, stage and microscopic aggressiveness, but patients with the same presentation can still have widely divergent outcomes. Researchers from Vanderbilt-Ingram Cancer Center have discovered that differences in tumor mutation burden are a major reason for this divergence.
Liquid biopsy test may detect early-stage and low DNA-shedding cancers
May. 31, 2023—Vanderbilt research shows that a liquid biopsy-based multicancer early detection (MCED) test could detect 12 types of cancers, including low DNA-shedding cancers and early-stage cancers.
Lovly elected to American Association for Cancer Research board
May. 11, 2023—Christine Lovly, MD, PhD, has been elected to the American Association for Cancer Research board of directors.
Trial combines novel therapies for head and neck cancer
Apr. 27, 2023—Vanderbilt is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.
VICC Scientific Retreat focuses on emerging technologies
Apr. 26, 2023—The Vanderbilt-Ingram Cancer Center 24th Annual Scientific Retreat will be held from 8:30 am to 3 pm, May 23, in the Vanderbilt Student Life Center.
